|
|
|
Insider
Information: |
Evnin Luke |
Relationship: |
10% Owner |
City: |
Boston |
State: |
MA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
15 |
|
Direct
Shares |
330,044 |
|
Indirect Shares
|
35,767,143 |
|
|
Direct
Value |
$449,921 |
|
|
Indirect Value
|
$125,579,860 |
|
|
Total
Shares |
36,097,187 |
|
|
Total
Value |
$126,029,782 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
1
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
1
|
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
Percentage
Gain/Loss : |
0.0%
|
-18.7%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Oscient Pharmaceuticals Corp |
OSCIQ |
Director |
|
0 |
2006-01-05 |
2,272,935 |
Premium* |
|
Idenix Pharmaceuticals Inc |
IDIX |
10% Owner |
2004-07-27 |
0 |
2004-07-27 |
4,797,991 |
Premium* |
|
Rigel Pharmaceuticals Inc |
RIGL |
10% Owner |
2004-07-02 |
0 |
2004-07-02 |
1,833,597 |
Premium* |
|
iPass Inc |
IPAS |
10% Owner |
2004-02-09 |
26,043 |
2004-02-09 |
262,533 |
Premium* |
|
Hemosense Inc |
HEM |
10% Owner |
2005-07-01 |
0 |
2007-11-06 |
0 |
Premium* |
|
American Cryostem Corporation |
CRYO |
10% Owner |
2005-07-13 |
0 |
2005-07-19 |
2,931,531 |
Premium* |
|
Radius Health Inc. |
RDUS |
Former 10% stockholder |
|
0 |
2016-09-27 |
3,887,502 |
Premium* |
|
Pacira Pharmaceuticals, Inc. |
PCRX |
Director |
2013-06-13 |
0 |
2013-06-13 |
824,255 |
Premium* |
|
Syndax Pharmaceuticals Inc |
SNDX |
Director, 10% Owner |
2016-03-08 |
0 |
2016-03-08 |
2,168,691 |
Premium* |
|
Harpoon Therapeutics, Inc. |
HARP |
Former 10% Owner |
2019-02-12 |
0 |
2021-04-15 |
3,220,844 |
Premium* |
|
Repare Therapeutics Inc. |
RPTX |
10% Owner |
2020-06-23 |
0 |
2020-06-23 |
3,003,772 |
Premium* |
|
Oncorus, Inc. |
ONCR |
Director, 10% Owner |
|
0 |
2020-10-06 |
2,492,843 |
Premium* |
|
Turmeric Acquisition Corp. |
TMPM |
Chief Executive Officer |
2020-10-20 |
0 |
2020-10-20 |
415,500 |
Premium* |
|
Werewolf Therapeutics, Inc. |
HOWL |
Director, 10% Owner |
|
0 |
2021-05-04 |
4,284,172 |
Premium* |
|
Tcr2 Therapeutics Inc. |
TCRR |
10% Owner |
2023-05-22 |
304,001 |
2023-05-22 |
3,370,977 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
107 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 2 of 5
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
TCRR |
Tcr2 Therapeutics Inc. |
10% Owner |
|
2023-05-22 |
4 |
OE |
$0.74 |
$131,919 |
D/D |
178,269 |
374,171 |
0 |
- |
|
TCRR |
Tcr2 Therapeutics Inc. |
10% Owner |
|
2023-05-22 |
4 |
S |
$1.88 |
$131,920 |
D/D |
(70,170) |
304,001 |
0 |
% |
|
OSCIQ |
Oscient Pharmaceuticals C... |
Director |
|
2005-08-24 |
4 |
S |
$2.23 |
$446,000 |
I/I |
(200,000) |
6,387,050 |
|
- |
|
OSCIQ |
Oscient Pharmaceuticals C... |
Director |
|
2005-08-22 |
4 |
S |
$2.28 |
$456,680 |
I/I |
(200,000) |
6,587,050 |
|
- |
|
OSCIQ |
Oscient Pharmaceuticals C... |
Director |
|
2005-08-30 |
4 |
S |
$2.28 |
$228,000 |
I/I |
(100,000) |
6,287,050 |
|
- |
|
OSCIQ |
Oscient Pharmaceuticals C... |
Director |
|
2005-08-31 |
4 |
S |
$2.30 |
$3,475,000 |
I/I |
(1,500,000) |
4,787,050 |
|
- |
|
OSCIQ |
Oscient Pharmaceuticals C... |
officerTitle |
|
2005-12-14 |
4 |
AS |
$2.30 |
$122,452 |
I/I |
(53,240) |
3,967,835 |
|
- |
|
OSCIQ |
Oscient Pharmaceuticals C... |
officerTitle |
|
2005-12-16 |
4 |
AS |
$2.30 |
$395,600 |
I/I |
(172,000) |
3,565,535 |
|
- |
|
OSCIQ |
Oscient Pharmaceuticals C... |
officerTitle |
|
2005-12-21 |
4 |
AS |
$2.30 |
$587,469 |
I/I |
(255,000) |
3,308,235 |
|
- |
|
OSCIQ |
Oscient Pharmaceuticals C... |
officerTitle |
|
2005-12-29 |
4 |
AS |
$2.30 |
$11,270 |
I/I |
(4,900) |
2,362,835 |
|
- |
|
OSCIQ |
Oscient Pharmaceuticals C... |
officerTitle |
|
2005-12-30 |
4 |
AS |
$2.30 |
$74,290 |
I/I |
(32,300) |
2,330,535 |
|
- |
|
OSCIQ |
Oscient Pharmaceuticals C... |
officerTitle |
|
2006-01-04 |
4 |
AS |
$2.30 |
$10,810 |
I/I |
(4,700) |
2,325,835 |
|
- |
|
OSCIQ |
Oscient Pharmaceuticals C... |
officerTitle |
|
2005-12-15 |
4 |
AS |
$2.32 |
$534,135 |
I/I |
(230,300) |
3,737,535 |
|
- |
|
OSCIQ |
Oscient Pharmaceuticals C... |
officerTitle |
|
2005-12-27 |
4 |
AS |
$2.32 |
$301,080 |
I/I |
(130,000) |
2,446,935 |
|
- |
|
OSCIQ |
Oscient Pharmaceuticals C... |
officerTitle |
|
2005-12-28 |
4 |
AS |
$2.33 |
$184,290 |
I/I |
(79,200) |
2,367,735 |
|
- |
|
OSCIQ |
Oscient Pharmaceuticals C... |
Director |
|
2005-08-19 |
4 |
S |
$2.35 |
$383,168 |
I/I |
(160,000) |
6,787,050 |
|
- |
|
OSCIQ |
Oscient Pharmaceuticals C... |
officerTitle |
|
2005-12-19 |
4 |
AS |
$2.36 |
$5,428 |
I/I |
(2,300) |
3,563,235 |
|
- |
|
OSCIQ |
Oscient Pharmaceuticals C... |
Director |
|
2006-01-05 |
4 |
AS |
$2.36 |
$124,590 |
I/I |
(52,900) |
2,272,935 |
0 |
- |
|
OSCIQ |
Oscient Pharmaceuticals C... |
officerTitle |
|
2005-12-23 |
4 |
AS |
$2.37 |
$1,079,033 |
I/I |
(455,000) |
2,576,935 |
|
- |
|
OSCIQ |
Oscient Pharmaceuticals C... |
officerTitle |
|
2005-12-22 |
4 |
AS |
$2.38 |
$658,174 |
I/I |
(276,300) |
3,031,935 |
|
- |
|
OSCIQ |
Oscient Pharmaceuticals C... |
Director |
|
2005-09-16 |
4 |
AS |
$2.41 |
$252,588 |
I/I |
(105,000) |
4,061,075 |
|
- |
|
OSCIQ |
Oscient Pharmaceuticals C... |
Director |
|
2005-09-19 |
4 |
AS |
$2.41 |
$96,324 |
I/I |
(40,000) |
4,021,075 |
|
- |
|
OSCIQ |
Oscient Pharmaceuticals C... |
Director |
|
2005-09-12 |
4 |
S |
$2.44 |
$500,938 |
I/I |
(205,000) |
4,240,050 |
|
- |
|
OSCIQ |
Oscient Pharmaceuticals C... |
Director |
|
2005-09-13 |
4 |
S |
$2.44 |
$121,855 |
I/I |
(50,000) |
4,190,050 |
|
- |
|
OSCIQ |
Oscient Pharmaceuticals C... |
Director |
|
2005-09-14 |
4 |
S |
$2.45 |
$58,756 |
I/I |
(23,975) |
4,166,075 |
|
- |
|
107 Records found
|
|
Page 2 of 5 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|